Search Results
Eunice Wang, MD, regarding evolving treatment considerations for FLT3 mutated AML
Eunice Wang, MD, on strategies for frail AML patients who do not qualify for intensive therapy
Eunice Wang, MD, considers approaches for clinicians when managing frail AML patients
Discussing FLT3-mutated AML: top ASH data, triplets, and exciting future strategies
The promise of combining venetoclax with gilteritinib for the treatment of FLT3-mutated AML
Clinical trials investigating treatment approaches for FLT3-mutated and IDH-mutated AML patients
Mechanisms of gilteritinib resistance in FLT3-mutated AML
Acute Myeloid Leukemia: Incorporating Novel Treatment Approaches into Clinical Pathways
Professor Eunice Wang, M.D. - Phase III CASCADE study
FLT3 mutational status can change between diagnosis and relapse in patients with AML
Eunice S. Wang, MD, discusses the toxicity of the CPX-351 (Vyxeos) in a phase III study
ADMIRAL update: co-occurrence of DNMT3A, NPM1 & FLT3 mutations in patients treated with gilteritinib
